Autoantibodies to the β1-Adrenoceptor from Patients with Periodontitis as a Risk Factor for Cardiac Dysfunction by Segovia, Marcela et al.
International Scholarly Research Network
ISRN Dentistry
Volume 2011, Article ID 791393, 9 pages
doi:10.5402/2011/791393
Research Article
Autoantibodiesto the β1-Adrenoceptor fromPatientswith
PeriodontitisasaRiskFactorforCardiacDysfunction
Marcela Segovia,1 SilviaReina,1,2 EnriBorda,1,2 and Leonor Sterin-Borda1,2
1Pharmacology Unit, School of Dentistry, University of Buenos Aires, 1122AAH Buenos Aires, Argentina
2Argentine National Research Council (CONICET), Buenos Aires, Argentina
Correspondence should be addressed to Leonor Sterin-Borda, leo@farmaco.odon.uba.ar
Received 23 May 2011; Accepted 6 July 2011
Academic Editors: D. Grenier, M. H. Parkar, and J. Walters
Copyright © 2011 Marcela Segovia et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Thepresenceofserumautoantibodiesinperiodontitis(P)patientsagainstβ1-adrenoceptor(β1-AR),usingcardiacmembranesora
syntheticβ1-ARpeptidecorrespondingtothesecondextracellularloopofhumanβ1-ARasantigens,permitustodetectcirculating
antibodyfrom40Ppatientsbutnotin20normalindividuals(control).Simultaneously,thePpatientsexhibitedadecreaseinHRV.
Anti-β1-AR IgG titters correlated with the decrease in HRV of the same patients and the anti-β1-AR peptide IgG displayed partial
agonist-like activity and modiﬁed the contractility of isolated atria, produced cyclic nucleotides, and inhibited the β1-AR agonistic
activity of isoproterenol. We demonstrated in this study an association between periodontitis infection and an increased risk of
cardiac disease, thereby highlighting the role of anti-β1-AR autoantibodies in alteration of myocardial contractility.
1.Introduction
Cardiovascular disease occurs as a result of a complex set of
genetic and environmental factors [1]. Although the identity
of the traditional risk factors has been established, they do
not fully account for the risk of cardiovascular disease, sug-
gesting that other mechanisms contribute to the pathogenic
process [2]. Recently, several lines of evidence have impli-
cated chronic inﬂammation in the etiology of cardiovascular
disease [3].
Periodontitis is an inﬂammatory disease of tooth-sup-
porting structures that leads to the destruction of connective
tissue, loss of periodontal attachment, and resorption of
alveolar bone [4].
The pathogenesis of the disease involves essential im-
munological factors associated with infections caused by
bacteria into subgingival plaque [5]. Among the immuno-
logical factors, local synthesis of biological products (e.g.,
enzymesproducedbycellsofthesupportingtissue)aswellas
bacterial-speciﬁc secretion of immunoglobulin (Ig), soluble
inﬂammatory mediators, and/or cellular/tissue degradation
products has been described [6–9]. It has been shown that
endotoxins of plaque microorganisms penetrate gingival
tissues and enter the bloodstream in suﬃcient numbers
to cause a systemic lipopolysaccharide-speciﬁc antibody re-
sponse [10].
However, in periodontal disease during the process of
combatingbacterialinfection,theimmunesystemmaycause
localized tissue damage and activate the systemic humoral
immune response [11, 12]. Thus, the susceptibility to, and
progression of, the disease is dependent upon not only
the virulence of the microbial pathogens, but also the host
response to regulation of tissue destruction.
Initial studies of autoimmunity in the pathogenesis of
periodontal disease focused on detection of autoantibod-
ies directed towards various self-antigens [13–15], such
as autoantibodies against human gingival ﬁbroblasts [16,
17]. Speciﬁcally, these antigingival ﬁbroblast autoantibodies
could interact with β1-ARs exhibiting adrenergic agonistic
activity.
Moreover, autoantibodies with immune reactivity
againstβ1-ARsofthemyocardiumhavebeendescribedinthe
sera of patients with diﬀerent cardiomyopathies associated
with infection with parasites and viruses [18–22]. Increasing
evidence indicates that periodontal disease is a risk factor
for cardiovascular disease and stroke [23, 24]. The main2 ISRN Dentistry
underlying pathological pathway for cardiomyopathy
associated with periodontal disease is atherosclerosis [2].
Increasing evidence suggests that the progression of athero-
sclerosis arises from a combination of dysfunction and
inﬂammation of the endothelium. Inﬂammatory mediators
derivedfrominfectedperiodontaltissueorperiodontopathic
bacteria (or their products) could induce dysfunction of
endothelial cells [2].
We demonstrated that serum autoantibodies from pa-
tients with periodontitis could react with the myocardial
surface and with human β1-ARs. A correlation between the
serum antibodies against myocardial β1-ARs and alteration
in heart rate variability (HRV) could be determined. The
capacity of β1-AR autoantibodies to modify atria contractil-
ity in vitro was also assessed.
2. Patientsand Methods
2.1. Patients. The study group consisted of 40 male patients
(mean age: 41 years; range: 32–50 years) with periodontitis
attending periodontology clinics in the metropolitan area of
Buenos Aires. Twenty healthy male subjects (mean age: 38
years; range: 30–46 years) were used as controls. The char-
acteristic signs of periodontitis included the following: loss
of clinical attachment; horizontal or/and angular alveolar
bone loss; periodontal pocket formation; gingival inﬂam-
mation. To be included in the study, at least six sites with
ongoing periodontal disease were required. Measurements
in patients with periodontitis included sites with alveolar
bone loss >2mm and pocket depth >5mm with bleeding
and attachment loss >3mm. In healthy subjects (control
group), the probing depth was <3mm and attachment loss
was <2mm. None of the subjects (patients in group I
and controls in group II) had systemic illnesses and they
were not smokers. Patients had not received periodontal
treatment or antibiotics within the preceding 5 months or
anti-inﬂammatory drugs 3 weeks before the study. Also, it
c a nb es e e ni nT a b l e s1 and 2 the general characteristic of the
studypopulationsandselectionindex.Allpatientsconsented
to participate in the study. The investigation was conducted
according to the tenets of the Declaration of Helsinki.
2.2. HRV. The 20 patients with periodontitis and 20 normal
subjects were studied according to a previous report [25].
Heart rate was recorded using an Oxford Medilog 2–24
miniatureanalogtaperecorder(OxfordInstrumentsMedical
Systems, Abingdon, UK). The recording speed was 2mms−1.
HRV was assessed from RR-interval ﬁles generated from
10pm to 8am analyzed in hourly epochs. The summary
time-domainstatisticalmeasuresofHRVcalculatedincluded
the HRV long-term standard deviation of all NN (SDNN)
indices. These indices represent variability over heart cycles
and estimate high-frequency variation in the heart rate [25].
2.3. Human Sera and IgG Puriﬁcation. Sera and the corre-
spondingIgGwereobtainedfrompatientswithperiodontitis
(group I) and from normal individuals (group II). Six
milliliters of blood were obtained by venipuncture. Blood
samples were allowed to clot at room temperature. The
serum was separated by centrifugation at 2000×ga n d
stored at −20◦C until used in assays. IgG was obtained by
precipitation followed previous reports [17, 18].
2.4. Puriﬁcation of Antipeptide Antibodies by Aﬃnity Chro-
matography. The IgG fraction of group-I patients was
independently subjected to aﬃnity chromatography on the
synthesized peptide covalently linked to Aﬃ-Gel 15 (Bio-
Rad, Richmond, CA, USA). The IgG fraction was loaded
on the aﬃnity column equilibrated with phosphate-buﬀered
saline (PBS) according to previous reports [16, 17].
2.5. Membrane Preparation. Cardiac membranes from male
rat Wistar strain were prepared as previously described
[17, 18]. In brief, cells or atria were homogenized in an
Ultra-Turrax homogenizer (IKA, Wilmington, NC, USA) at
4◦C in 6 volumes of potassium phosphate buﬀer, 1mM
MgCI2, 0.25M sucrose (pH 7.5) supplemented with 0.1mM
phenylmethyl sulphonyl ﬂuoride (PMSF), 1mM ethylenedi-
amine tetra-acetic acid (EDTA), 5μgm L −1 leupeptin, 1μM
bacitracin, and 1μM pepstatin A. The homogenate was
centrifuged twice for 10min at 3000×g, then at 10,000×g
and 40,000×ga t4 ◦C for 15min and 90min, respectively.
The resulting pellets were suspended in 50mM phosphate
buﬀer fortiﬁed with the same protease inhibitors (pH 7.5).
2.6. ELISA Assay. Fifty micromililiters of peptide solution
at 50μg/mL concentration or puriﬁed cardiac membranes
(50μg/mL) in 0.1M Na2CO3 buﬀer (pH 9.6) were used to
coat microtiter plates at 4◦C overnight. After blocking the
wells with 2% bovine serum albumin in PBS for 1 h at 37◦C,
10μL of a 1/30 dilution of sera of diﬀerent concentrations or
puriﬁed IgG from groups I and II were added in triplicate
and allowed to react with the peptide for 2h at 37◦C. After
thoroughly washing the wells with 0.05% Tween 20 in PBS,
100μL of 1:6000 goat anti-human IgG alkaline phosphate
conjugate antibodies were added and incubated for 1h
at 37◦C. After extensive washing, p-nitrophenylphosphate
(1mg/mL) was added as the substrate and the reaction
stopped after 30min. Optical density (OD) was measured
at 405nm with an ELISA reader. As a negative control,
nonantigen paired wells with M1 cholinergic peptide and
wells with no primary antiserum were also used. The results
for each sample were expressed as the mean ± standard error
of the mean (s.e.m.) of triplicate values.
2.7. Contractile Study. Male rats Wistar strain (200–250g)
were decapitated and atria quickly removed. Atria were
placed in a glass chamber containing Krebs–Ringer bicar-
bonate (KRB) solution (pH 7.4) that was gassed with 5%
CO2 inoxygenat30◦C.Afterastabilizationperiodof30min,
spontaneous tension and frequency were recorded using a
force transducer coupled to an ink-writing oscillograph, as
previously described [18].
2.8. Assays for Cyclic Adenosine Monophosphate (cAMP) and
Cyclic Guanosine Monophosphate (cGMP). Rat atria (10mg)ISRN Dentistry 3
Table 1: Characteristic of the study populations.
Demography and risk factors Periodontitis patients group I (n = 40) Healthy subjects group II (n = 20)
Gender
Male 36 18
Female 4 2
Education level
Elementary school 38 18
High school 2 2
BMI (range kg/m2) From 20 to 25 From 19 to 22
Measure blood pressure (mmHg)
Measure SBP (mean ± SD) 138 ± 20 118 ± 14
Measure DBP (mean ± SD) 87 ± 12 75 ± 10
Laboratory examination
Cholesterol total (mean ± SD), mg/dl 170 ± 21 176 ± 22
LDL (mean ± SD), mg/dl 129 ± 14 130 ± 21
HDL (mean ± SD), mg/dl 34 ± 10 32 ± 11
BMI: Body Mass Index (range ≥27kg/m2); SBP: Systolic Blood Pressure. DBP: Diastolic Blood Pressure; LDL: Low-density lipoprotein; HDL: High-density
lipoprotein.
Table 2: Periodontitis selection index.
Parameters Numerical ranges
PPD ≥6mm
CAL ≥6mm
PPD: pocket probing depth; CAL: clinical attachment loss.
were incubated in 1mL KRB for 30min and the β1 agonist
isoproterenol (ISO) added in the last 15min. When blockers
were used, they were added 25min before the addition
of ISO. After incubation, atria were homogenized in 2mL
of absolute ethanol and centrifuged at 6000×gf o r1 5 m i n
at 4◦C. Pellets were then rehomogenized in ethanol-water
(2:1). Supernatants were collected and evaporated to dry-
ness as described above. Cyclic AMP or cyclic GMP in the
residue was dissolved in 400μL of 0.05M sodium acetate
buﬀer (pH 6.2). For determination of nucleotides, we used
ELISA employing the protocol of production of cAMP and
cGMP from Amersham Biosciences (Piscataway, NJ, USA).
Results were expressed in pico moles per milligram of wet
weight of tissue (pmol/mg tissue ww).
2.9. Drugs. Stock solutions of ISO and atenolol were freshly
prepared before each experiment. The β1 peptide corre-
sponded to the sequence of the second extracellular loop
of the human β1-AR (HWWRA ESDEA RRCYN DPKCC
DFVTN RC). An unrelated peptide derived from the sec-
ond extracellular loop of the human M2 cholinoreceptor
(VRTVE DGECY IQFFS NAAVT FGTA) was used as a
control. Radioactive material, synthetic peptides, and β-
adrenergic antagonists were from Dupont/New England
Nuclear (Boston, MA, USA), Sigma Genosys (St. Louis, MO,
USA),andSigma-Aldrich(St.Louis,MO,USA),respectively.
2.10. Statistical Analysis. The Student’s t-test for unpaired
values was used to determine the levels of signiﬁcance.
Analysis of variance (ANOVA) and a post hoc test (Dunnett’s
method and Student-Newman-Keuls test) were employed
when pairwise multiple comparison procedures were neces-
sary. Diﬀerences between means were considered signiﬁcant
if P<0.05.
3. Results
ELISA assays were carried out to demonstrate if there was a
correlation between the level of IgG in the serum of patients
with periodontitis and cardiac membranes and the β1-AR.
Figure 1 shows the OD values for sera from patients with
periodontitis (group I) and normal subjects (group II) using
rat cardiac membrane (a) and β1-AR synthetic peptide (b) as
coating antigens. The OD values obtained from group-I sera
werealwaysmorethantwostandarddeviations(>2SD)from
those of normal individuals. Figure 1(c) shows a positive
correlation between serum anticell cardiac membrane and
anti-β1-AR peptide antibodies of the individual sera from
group I. It was noted that 34/40 (85%) and 32/40 (80%) of
patients’ sera reacted positively against cardiac membranes
and β1-AR synthetic peptide, respectively. When unrelated
synthetic peptide (M2 cholinoceptor peptide) was used as a
coating antigen, IgG from group I and from group II gave
negative results (data not shown).
Knowing that the β1-AR is involved in regulating various
cardiac parameters (including heart rate and HRV), we
evaluated the HRV in 20 patients with periodontitis whose
sera reacted positively against β1 synthetic peptide and in 20
normal individuals who acted as controls. The diﬀerences
between patients with periodontitis and normal subjects
with respect to the SDNN index are shown in Figure 2(a).4 ISRN Dentistry
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Figure 1: Immunoreactivity of circulating IgG antibodies against cardiac membrane (a) or against β1-AR synthetic peptide (b). The optical
density(OD)forserumsample(1/30dilution)from40periodontitispatients(groupI)or20normalindividuals(groupII)wereevaluatedby
duplicate. Values are mean ± SD. Cutoﬀ values of OD 0.180 and 0.210 for cardiac membranes and anti-β1-ARsynthetic peptide, respectively.
Correlation (c) between titers of serum anti-β1-AR peptide IgG and anticardiac membrane IgG from periodontitis patients. Anti-β1-AR
peptide IgG titters were plotted as function of anti cardiac membranes. The values correspond to 40 periodontitis patients.ISRN Dentistry 5
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Figure 2: (a) Heart rate variability long-term standard deviation (SDNN) index in 20 patients with periodontitis (group I) and in 20 normal
individuals (group II). (b) Correlation between values of the SDNN index and titers of serum anti-β1-AR peptide IgG. The SDNN index was
plotted as a function of serum titers of anti-β1-AR peptide IgG corresponding to the same patients.6 ISRN Dentistry
Table 3: Inﬂuence of β1 blockade on the stimulatory and inhibitory eﬀects of anti-β1-AR peptide IgG.
Addition dF/dt cAMP cGMP
Basal 1.8 ± 0.21 0.38 ± 0.03 0.041 ± 0.004
β1-AR IgG (5 × 10−8 M) 3.9 ± 0.32∗ 1.25 ± 0.11∗ 0.051 ± 0.004
β1-AR IgG (5 × 10−8 M) + atenolol 2.1 ± 0.19∗∗ 0.41 ± 0.04∗∗ —
β1-AR IgG + β1-AR peptide 2.3 ± 0.23∗∗ 0.42 ± 0.03∗∗ —
Normal IgG (5 ×10−8 M) 1.9 ± 0.18 0.40 ± 0.02 0.039 ± 0.04
Basal 2.1 ± 0.22 0.40 ± 0.03 0.042 ± 0.004
β1-AR IgG (5 ×10−7 M) 0.6 ± 0.05∗ 0.21 ± 0.02∗ 0.350 ± 0.03∗
β1-AR IgG (5 ×10−7 M) + atenolol 1.7 ± 0.15∗∗ 0.38 ± 0.03∗∗ 0.122 ± 0.02∗∗
β1-AR IgG + β1-AR peptide 1.9 ± 0.20∗∗ 0.37 ± 0.02∗∗ 0.101 ± 0.02∗∗
Normal IgG (5 ×10−7 M) 2.0 ± 0.19 0.42 ± 0.03 0.043 ± 0.003
Values are mean ± s.e.m. of ten patients with periodontitis in each group carried out in duplicate. Contractility (dF/dt: g/s), and levels of cAMP (pmol/mg
tissue ww) and cGMP (pmol/mg tissue ww) were measured after incubation for 15min with rat atria in the presence of anti-β1-AR peptide IgG (β1-AR IgG)
and normal IgG or in the absence (basal) of IgG. Atenolol (5×10−7 M) and β1-AR peptide (5×10−5 M) were added before the IgG. ∗P<0.001 versus basal;
∗∗P<0.001 versus β1-AR IgG alone.
There was a signiﬁcant decrease in HRV (mean ± SD: 65.1 ±
9.2) in patients with periodontitis in comparison with the
control group (mean ± SD: 90.3 ± 10). When the SDNN
index was plotted as a function of serum titers, anti-β1-AR
peptide IgG from each patient with periodontitis showed
a negative correlation between serum anti-β1-AR peptide
antibodies and the SDNN index (Figure 2(b)).
We observed that patients with periodontitis showed a
profound alteration in cardiac contractility in vivo,s ow e
wanted to ascertain if serum anti-β1-AR antibodies could
trigger cardiac β1-AR functional alterations in atria. For this
purpose, we selected the 20 patients with periodontitis who
showed a decrease in HRV and whose sera were positive
against β1-adrenergic synthetic peptide in the ELISA assay.
The IgG fraction was independently subjected to aﬃnity
chromatography and eluted from the column covalently
linked to β1-adrenergic synthetic peptide (anti-β1-AR pep-
tide IgG). Increasing concentrations of anti-β1-AR peptide
IgG were applied to isolated spontaneously beating rat
atria and changes in the magnitude of contractility (dF/dt)
measured (Figure 3).
Anti-β1-AR peptide IgG behaved as a partial β1-adren-
ergic agonist; increasing dF/dt at low concentrations and at
higher concentrations, autoantibodies decreased dF/dt (Fig-
ures 3(a) and 3(b)). The stimulatory and inhibitory eﬀects
were accompanied by modiﬁcation of cAMP production
(Figure 3(a)) and cGMP production (Figure 3(b)). cAMP
production correlated positively with the stimulatory eﬀect
of the antibodies (Figure 3(c)), but cGMP production cor-
related negatively with the inhibitory eﬀect of the antibodies
(Figure 3(d)). Table 3 shows the eﬀect of blockade upon the
eﬀect of IgG on dF/dt, cAMP and cGMP. For the β1-AR,
the stimulatory and inhibitory eﬀects were almost abolished
by pretreatment of atria with 1 × 10−7 Ma t e n o l o l( β1-
AR antagonist) and by 1 × 10−5 M β1-adrenergic synthetic
peptide. The IgG from normal subjects and the nonpeptide
fraction gave negative results (data not shown).
Toascertainifanti-β1-ARpeptideIgGinteractedwiththe
samecardiacβ1-ARepitopeasanauthenticagonist(ISO),we
studied the action of anti-β1-AR peptide antibody upon ISO.
Themaximalpositiveeﬀectsof5×10−8 MISOondF/dt(g/s:
5.3 ± 0.5, n = 5) and the cAMP stimulation (pmol/mg tissue
ww: 2.8 ± 0.3, n = 5) were blunted by 5 ×10−7 M anti-β1-AR
peptide IgG.
4. Discusion
We previously demonstrated that patients with periodontitis
have functional serum IgG that interacts with the β1-AR
of gingival ﬁbroblasts. In the present study, we conﬁrmed
the presence of anti-β1-AR autoantibodies in the sera of
patients with periodontitis and provided evidence that
these sera can also recognize the cardiac membranes of
rats. Most of the sera that reacted positively against rat
cardiac membranes showed positive immune reactivity to
human β1-AR synthetic peptide. Furthermore, a signiﬁcant
correlation between anticardiac membrane antibodies and
anti-β1-AR peptide IgG was observed.
Using a synthetic peptide with an identical amino acid
sequence of the second extracellular loop of human β1-AR,
we established that the β1-AR is a target for the anticardiac
autoantibodies described in patients with periodontitis. Due
to the strong homology between rodent and human β1-
AR peptides [26], one can assume that this is the one
recognized by the autoantibodies. It has been shown that
the second extracellular loop of cardiovascular G-protein-
coupled receptors is an antigenic target for the generation
of autoantibodies in patients with cardiomyopathy [27].
Therefore, we studied the β1-AR-mediated eﬀectof autoanti-
bodiesonisolatedratatriausingaﬃnity-puriﬁedanti-β1-AR
peptide IgG from patients with periodontitis.
HRV is a powerful predictor of cardiovascular mortal-
ity in healthy people, those who have had a myocardial
infarction, and in patients with heart failure. An elevated
resting heart rate, reduced HRV, or both are negative
prognostic factors independent of other clinical parameters,
including left ventricular function [28]. Impaired control
of HRV is linked to a deleterious sympathovagal imbalanceISRN Dentistry 7
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Figure 3:Eﬀectofincreasingconcentrationsofanti-β1-ARpeptideIgG(IgG)oncontractility(dF/dt)andproductionofcAMPandcGMPin
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characterized by predominance of the sympathetic nervous
system [28].
In the present study, the ﬁnding of a correlation between
decrease in HRV and the presence of serum anticardiac
membrane autoantibodies and anti-β1-AR autoantibodies
in patients with periodontitis allows us to suggest that the
lower HRV observed in such patients is due to ﬁxation of
antibodies upon receptors. HRV alteration may be a conse-
quenceofactivationoftheβ1-ARinducedbyantibodyβ1-AR
interaction on the cardiac sarcolemma.
We also provide evidence that isolated fractions of
IgG enriched in anti-β1-AR peptide antibody could display
partial agonistic activity on contractility in isolated atria.
The partial agonistic activity of autoantibodies observed
in vitro mimics the action on HRV of the partial β1-
adrenergic agonist celiprolol described in vivo. However, the
combination of celiprolol with atenolol did not prevent the
fall in HRV triggered by the partial agonist [25]. Hence,
the antibody-mediated partial β1 agonistic activity could
be responsible for the decrease in HRV in patients with
periodontitis.
The increase in contractility observed at low concen-
trations of IgG correlated with the increase in production
of cAMP, whereas the decrease in contractility triggered by
higher concentrations of IgG correlated with an increase in
cGMP production. The increase and decrease in contractility
are related to β1-AR function because they were blunted
by atenolol. The increase in cGMP production which could
limit the increase in contractility of β-adrenergic stimulation
of isolated rat atria has been established [29].
The interaction of anti-β1-AR autoantibodies with the
receptor has two functional implications: (i) it directly
modiﬁes the sympathetic activity of the myocardium; (ii) it
decreases the eﬀectiveness of the authentic agonist ISO. This
raises the question: could there be a common explanation
for the abnormal sympathetic activity in the cardiovascular
system mediated by cardiac β1-AR autoantibodies? If so,
antibody ﬁxation could increase sympathetic activity for
an extended period and result in a chronically elevated
heart rate. Simultaneously, the antagonistic activity of the
autoantibodies could lead to deleterious sympathovagal
imbalance, resulting in functional deregulation associated
with pathologic remodelling, myocyte apoptosis, and alter-
ation of calcium handling that leads to myocardial ischemia,
a decrease in contractile function, and an increased risk of
ventricular arrhythmias [30].
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